CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 121 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $125,000 | -90.8% | 15,100 | -91.5% | 0.46% | -36.5% |
Q1 2020 | $1,357,000 | -19.8% | 176,993 | -13.1% | 0.72% | +264.1% |
Q4 2019 | $1,691,000 | -32.0% | 203,600 | -39.6% | 0.20% | -37.7% |
Q3 2019 | $2,488,000 | -48.8% | 337,164 | -22.1% | 0.32% | -5.6% |
Q2 2019 | $4,858,000 | +4.4% | 432,981 | 0.0% | 0.34% | +56.7% |
Q1 2019 | $4,654,000 | +46.4% | 432,981 | +105.6% | 0.22% | -1.8% |
Q4 2018 | $3,180,000 | -23.4% | 210,600 | -6.2% | 0.22% | -8.0% |
Q3 2018 | $4,153,000 | -26.5% | 224,500 | -9.1% | 0.24% | -28.1% |
Q2 2018 | $5,648,000 | -31.7% | 247,100 | -15.0% | 0.33% | -37.3% |
Q1 2018 | $8,270,000 | +65.4% | 290,700 | +22.7% | 0.53% | +97.0% |
Q4 2017 | $5,000,000 | +16.2% | 236,900 | 0.0% | 0.27% | +16.0% |
Q3 2017 | $4,304,000 | +17.2% | 236,900 | 0.0% | 0.23% | +1.8% |
Q2 2017 | $3,671,000 | +109.1% | 236,900 | +132.9% | 0.23% | +104.5% |
Q1 2017 | $1,756,000 | +139.6% | 101,700 | +52.5% | 0.11% | +85.0% |
Q4 2016 | $733,000 | +96.0% | 66,700 | +179.0% | 0.06% | +100.0% |
Q3 2016 | $374,000 | -6.0% | 23,904 | -22.6% | 0.03% | -25.0% |
Q1 2016 | $398,000 | – | 30,900 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |